Viewing Study NCT05438420


Ignite Creation Date: 2025-12-25 @ 4:12 AM
Ignite Modification Date: 2025-12-26 @ 3:10 AM
Study NCT ID: NCT05438420
Status: RECRUITING
Last Update Posted: 2024-03-12
First Post: 2022-05-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Sponsor: Qurient Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module